Mehmet Artac
Mehmet Artac is an expert in Oncology at Necmettin Erbakan University (Turkey). As of November 2026, ScienceLeadR ranks Mehmet Artac in the top 1% of experts worldwide for Lung Neoplasms, Thoracic Neoplasms and Carcinoma. Mehmet Artac has authored 235 publications, the most recent in 2026, and is an investigator in 19 clinical trials, 5 of them ongoing. SLR score: 1,115 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Pharmacy - Immunology - Pulmonology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
Organizations
Career arc: 2006 - 2026
Number : 235
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 19
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
5 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Large Granular Lymphocytes in mNSCLC Treated With Nivolumab NCT07363811 — cells, lung, blood, lymphocytes, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, cytoplasm, small cell lung carcinoma, nivolumab, carcinoma | N/A | Recruiting | 2025 |
| ADAR1 Expression Level in Rectal Cancer NCT07108348 — adenosine deaminase, dna mismatch repair, immunohistochemistry, polymerase chain reaction, neoplasms, adenocarcinoma, colon, biopsy, adenosine, rectum, enzymes, neoadjuvant therapy, rectal neoplasms, therapeutics, tissues, real-time polymerase chain reaction, colonic neoplasms, rna, sensitivity and specificity | N/A | Recruiting | 2025 |
| The Impact of Probiotic on Survival and Treatment Response in Metastatic Non small Cell Lung Cancer Patients NCT06428422 — cells, lung, bifidobacterium animalis, neoplasms, carcinoma, non-small-cell lung, immunotherapy, lung neoplasms, small cell lung carcinoma, probiotics, bifidobacterium, nivolumab, therapeutics, microbiota, carcinoma | N/A | Recruiting | 2024 |
| Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited stage Small Cell Lung Cancer (LS SCLC) NCT06095583 — injections, cells, lung, neoplasms, disease progression, multiple chronic conditions, lung neoplasms, chemoradiotherapy, small cell lung carcinoma, antibodies, monoclonal, therapeutics, carcinoma | Phase 3 | Recruiting | 2023 |
| Effects of Ketogenic Diet in Overweight and Obese Women With Breast Cancer NCT05234502 — exercise, research design, quality of life, breast neoplasms, neoplasms, drug therapy, diet, polyneuropathies, breast, diet, ketogenic, neoadjuvant therapy, nutritional status, therapeutics, overweight, diet, healthy, chemotherapy, female, women | N/A | Not yet recruiting | 2022 |
LeadR Networks
Main global connection map